IRS1 and lung cancer: As subsequent molecular profiling identified an ALK rearrangement, the study proposed the IGF-1R–IRS-1 signaling axis as a potential therapeutic focus in ALK+ lung cancer, providing insights for upcoming clinical trials [164].